Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients

Autor: Margherita Maffioli, Toni Giorgino, Barbara Mora, Alessandra Iurlo, Elena Elli, Maria Chiara Finazzi, Marianna Caramella, Elisa Rumi, Maria Cristina Carraro, Nicola Polverelli, Mariella D'Adda, Simona Malato, Marianna Rossi, Alfredo Molteni, Alessandro Vismara, Cinzia Sissa, Francesco Spina, Michela Anghilieri, Daniele Cattaneo, Rossella Renso, Marta Bellini, Maria Luisa Pioltelli, Chiara Cavalloni, Daniela Barraco, Raffaella Accetta, Lorenza Bertù, Matteo Giovanni Della Porta, Francesco Passamonti

Publikováno v: Blood Advances, Vol 3, Iss 21, Pp 3196-3200 (2019)

Externí odkaz: https://doaj.org/article/abde1cc428324ea48f63a5890e5387b8

BID and the α-bisabolol-triggered cell death program: converging on mitochondria and lysosomes

Autor: Erika Lorenzetto, Irene Liparulo, Fabrizio Vinante, Isacco Ferrarini, Antonella Rigo, Cinzia Sissa, Elisabetta Cavalieri, Christian Bergamini, Elena Darra

Publikováno v: Cell Death and Disease, Vol 10, Iss 12, Pp 1-13 (2019)
Cell Death & Disease

α-Bisabolol (BSB) is a plant-derived sesquiterpene alcohol able to trigger regulated cell death in transformed cells, while deprived of the general toxicity in several mouse models. Here, we investigated the involvement of lysosomal and mitochondria

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54a6c7c999e3ea1e8f4e874383ca38ed
http://link.springer.com/article/10.1038/s41419-019-2126-8

Second primary malignancies in ruxolitinib-treated myelofibrosis: Real-world evidence from 219 consecutive patients

Autor: Elena Maria Elli, Toni Giorgino, Lorenza Bertù, Elisa Rumi, Chiara Cavalloni, Marianna Caramella, Alessandro Vismara, Daniela Barraco, Margherita Maffioli, Maria Chiara Finazzi, Mariella D'Adda, Francesco Spina, Daniele Cattaneo, Francesco Passamonti, Nicola Polverelli, Simona Malato, Maria Cristina Carraro, Alfredo Molteni, Barbara Mora, Alessandra Iurlo, Maria Luisa Pioltelli, Marianna Rossi, Rossella Renso, Raffaella Accetta, Matteo G. Della Porta, Michela Anghilieri, Marta Bellini, Cinzia Sissa

Publikováno v: Blood advances 3 (2019): 3196–3200. doi:10.1182/bloodadvances.2019000646
info:cnr-pdr/source/autori:Margherita Maffioli and Toni Giorgino and Barbara Mora and Alessandra Iurlo and Elena Elli and Maria Chiara Finazzi and Marianna Caramella and Elisa Rumi and Maria Cristina Carraro and Nicola Polverelli and Mariella D'Adda and Simona Malato and Marianna Rossi and Alfredo Molteni and Alessandro Vismara and Cinzia Sissa and Francesco Spina and Michela Anghilieri and Daniele Cattaneo and Rossella Renso and Marta Bellini and Maria Luisa Pioltelli and Chiara Cavalloni and Daniela Barraco and Raffaella Accetta and Lorenza Bert`u and Matteo Giovanni Della Porta and Francesco Passamonti/titolo:Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients/doi:10.1182%2Fbloodadvances.2019000646/rivista:Blood advances/anno:2019/pagina_da:3196/pagina_a:3200/intervallo_pagine:3196–3200/volume:3

Myeloproliferative neoplasms (MPNs) are clonal disorders that include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). Patients with MPNs have a higher risk than the general population of developing a lymphoid

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89a5b41a649ae26b37c0e831ce0956bf
https://hdl.handle.net/11379/569789

Hemostatic Agents for Bleeding: Recombinant-Activated Factor VII and Beyond

Autor: Francesco Frattini, Carlo Bonfanti, Massimo Franchini, Cinzia Sissa, Silvia Crestani

Publikováno v: Seminars in Thrombosis and Hemostasis. 41:342-347

A rapid restoration of hemostasis should be regarded as a primary goal for management of critical bleeding, which often represents a life-threatening condition. Among the various therapeutic strategies available in this clinical setting, we aim to su

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec0a9c190a2936c4aa696504fd380e20
https://doi.org/10.1055/s-0034-1381234

Recombinant activated factor VII in clinical practice: a 2014 update

Autor: Massimo Franchini, Cinzia Sissa, Francesco Frattini, Silvia Crestani, Carlo Bonfanti

Publikováno v: Journal of thrombosis and thrombolysis. 39(2)

Recombinant activated factor VII (rFVIIa) was initially developed to treat bleeding episodes in patients with congenital hemophilia and inhibitors. Due to the initial success in this clinical setting, its use has been extended to other coagulopathies

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a380fef20c677ef4d9117d793f8a590
https://pubmed.ncbi.nlm.nih.gov/25015059